Abiraterone 250 mg Tablets contain Abiraterone Acetate 250 mg, a prescription medicine used as part of treatment for certain advanced forms of prostate cancer. While Abiraterone can be an important component of prostate cancer treatment, patients should understand its possible side effects, safety precautions, monitoring requirements and potential drug interactions before starting therapy.
This guide explains the common Abiraterone 250 mg side effects, serious safety warnings, precautions and monitoring requirements. Abiraterone should be taken only under the supervision of a qualified healthcare professional.
What Is Abiraterone 250 mg?
Abiraterone Acetate is a CYP17 inhibitor that reduces androgen production. It is used with corticosteroid therapy, such as prednisone or prednisolone, for certain prostate cancer indications. The exact treatment regimen depends on the patient's condition and the prescribing information applicable to the product.
The 250 mg tablet is one available strength of Abiraterone Acetate. Patients should follow the dose and administration instructions provided by their oncologist or healthcare professional.
Common Abiraterone 250 mg Side Effects
The most frequently reported adverse reactions with Abiraterone Acetate include:
- Fatigue or tiredness
- Joint pain or arthralgia
- High blood pressure
- Nausea
- Swelling or edema
- Low potassium levels
- Hot flushes
- Diarrhea
- Vomiting
- Cough
- Headache
- Upper respiratory tract infection
Not every patient experiences these effects, and their severity can vary. Patients should inform their healthcare professional if side effects are persistent, worsening or interfere with daily activities.
Abiraterone 250 mg Serious Side Effects
Some adverse effects require particular medical attention. Abiraterone can cause mineralocorticoid-related effects, including high blood pressure, low potassium and fluid retention. These effects may be especially important for patients with cardiovascular conditions. Blood pressure, potassium levels and signs of fluid retention should be monitored during treatment.
Symptoms that should be reported promptly may include significant swelling of the legs or feet, dizziness, muscle weakness, confusion, faintness, headache or fast or irregular heartbeat.
Liver-Related Safety
Hepatotoxicity, or liver injury, is an important safety consideration with Abiraterone. Severe liver toxicity has been reported, including acute liver failure. Liver function tests are therefore required before and during treatment. Current prescribing information recommends monitoring ALT, AST and bilirubin, with particularly close monitoring during the first months of therapy.
Patients should immediately discuss symptoms such as unusual yellowing of the skin or eyes, dark urine, severe nausea or vomiting, or significant abdominal discomfort with their healthcare professional.
Abiraterone 250 mg Safety Precautions
Before starting Abiraterone treatment, patients should tell their doctor about existing medical conditions, especially:
- Heart or cardiovascular disease
- High blood pressure
- Low potassium
- Liver disease
- Diabetes
- Previous liver problems
- Other medicines or supplements currently being used
Patients with moderate or severe liver impairment may require special consideration or dose adjustment. The prescribing information includes specific recommendations for patients with hepatic impairment and for those who develop liver toxicity during treatment.
Abiraterone and Prednisone
Abiraterone is commonly administered with a corticosteroid such as prednisone as part of approved treatment regimens. Patients should take the corticosteroid exactly as prescribed and should not stop prednisone suddenly without medical advice, because adrenal insufficiency can occur.
Abiraterone 250 mg Drug Interactions
Abiraterone can interact with other medicines. Strong CYP3A4 inducers may affect Abiraterone exposure, while Abiraterone can also affect certain CYP2D6-substrate medicines. Patients should provide their doctor or pharmacist with a complete list of prescription medicines, over-the-counter products and supplements before treatment.
Patients with diabetes may also require additional monitoring because hypoglycemia has been reported in certain patients taking Abiraterone with specific antidiabetic medicines.
How to Take Abiraterone 250 mg Safely
Abiraterone tablets should be taken exactly as prescribed. For formulations requiring administration on an empty stomach, the tablet should be taken with water and food restrictions should be followed according to the applicable product prescribing information. Tablets should generally be swallowed whole rather than crushed or chewed.
Do not change the dose, stop treatment or start another medicine without consulting your healthcare professional.
Abiraterone 250 mg Safety Monitoring
Regular medical monitoring is an important part of Abiraterone treatment. Depending on the patient's condition, healthcare professionals may monitor:
- Blood pressure
- Serum potassium
- Liver function
- Fluid retention and swelling
- Symptoms of adrenal insufficiency
- Blood glucose in patients with diabetes
- Other laboratory parameters as clinically appropriate
Monitoring helps healthcare professionals identify potential treatment-related problems and determine whether treatment adjustments are required.
Frequently Asked Questions
Is Abiraterone 250 mg safe?
Abiraterone can be used as prescribed for appropriate patients, but it has important risks and requires medical monitoring. Patients should use it only under the supervision of their healthcare professional.
What are the most common Abiraterone 250 mg side effects?
Commonly reported effects include fatigue, joint pain, hypertension, nausea, edema, low potassium, hot flushes, diarrhea, vomiting, cough and headache.
Can Abiraterone affect the liver?
Yes. Liver toxicity is an important safety concern, and liver function should be monitored before and during treatment.
Can Abiraterone cause low potassium?
Yes. Abiraterone may cause hypokalemia. Healthcare professionals monitor potassium levels during treatment, particularly because significant hypokalemia can contribute to cardiovascular complications.
Abiraterone 250 mg Tablets Supplier in India
Global Pharma Trade provides pharmaceutical sourcing support for Abiraterone 250 mg Tablets in India, subject to product availability, prescription requirements and applicable regulatory conditions. Hospitals, pharmacies, distributors and eligible pharmaceutical buyers can contact Global Pharma Trade for product details, availability, pack information and quotation requirements.
Medical disclaimer: This article is for general educational and product-information purposes and does not replace advice from an oncologist, doctor or pharmacist. Always follow the prescribing information supplied with your specific product and your healthcare professional's instructions.
